Table III.
Change in Metabolic Parameters (Safety Seta)
| Aliskiren/HCTZ 300/25 mg (±AML 5 mg) (n=204) | HCTZ 25 mg (±AML 5 mg) (n=205) | |
|---|---|---|
| Fasting plasma glucose, mmol/Lb | ||
| Baseline | 5.9±1.4 | 6.1±1.6 |
| Week 8 | 6.3±2.2 | 6.4±1.7 |
| Change from baseline | 0.4±1.8 | 0.3±1.5 |
| Total cholesterol, mmol/L | ||
| Baseline | 5.1±1.0 | 4.9±1.1 |
| Week 8 | 5.2±1.2 | 5.0±1.2 |
| Change from baseline | 0.2±0.8 | 0.1±0.7 |
| HDL cholesterol, mmol/L | ||
| Baseline | 1.4±0.4 | 1.4±0.4 |
| Week 8 | 1.4±0.4 | 1.4±0.4 |
| Change from baseline | 0.0±0.2 | 0.0±0.2 |
| LDL cholesterol, mmol/L | ||
| Baseline | 3.1±0.9 | 2.9±0.9 |
| Week 8 | 3.2±1.0 | 3.0±1.0 |
| Change from baseline | 0.1±0.6 | 0.1±0.6 |
| Triglycerides, mmol/L | ||
| Baseline | 1.8±1.3 | 1.7±1.0 |
| Week 8 | 2.1±1.8 | 1.9±1.2 |
| Change from baseline | 0.3±1.3 | 0.2±0.8 |
Data are shown as mean ± standard deviation for patients with a value at both baseline and week 8. Abbreviations: AML, amlodipine; HCTZ, hydrochlorothiazide; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein. aSafety set includes all patients that received at least one dose of study medication. bAliskiren/HCTZ±AML, n=202; HCTZ±AML, n=205.